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D-mannose suppresses macrophage IL-1β
production
Simone Torretta 1, Alessandra Scagliola1, Luisa Ricci1, Francesco Mainini 1, Sabrina Di Marco1,
Ivan Cuccovillo 2, Anna Kajaste-Rudnitski 2, David Sumpton 3, Kevin M. Ryan3 & Simone Cardaci 1✉
D-mannose is a monosaccharide approximately a hundred times less abundant than glucose
in human blood. Previous studies demonstrated that supraphysiological levels of D-mannose
inhibit tumour growth and stimulate regulatory T cell differentiation. It is not known whether
D-mannose metabolism affects the function of non-proliferative cells, such as inflammatory
macrophages. Here, we show that D-mannose suppresses LPS-induced macrophage acti-
vation by impairing IL-1β production. In vivo, mannose administration improves survival in a
mouse model of LPS-induced endotoxemia as well as decreases progression in a mouse
model of DSS-induced colitis. Phosphomannose isomerase controls response of LPS-
activated macrophages to D-mannose, which impairs glucose metabolism by raising intra-
cellular mannose-6-phosphate levels. Such alterations result in the suppression of succinate-
mediated HIF-1α activation, imposing a consequent reduction of LPS-induced Il1b expression.
Disclosing an unrecognized metabolic hijack of macrophage activation, our study points
towards safe D-mannose utilization as an effective intervention against inflammatory
conditions.
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Macrophages are frontline cells of innate immunity,playing critical roles in the early promotion as well asresolution of inflammation. Such functional plasticity
depends on specific changes in their metabolic programs. An
increase in glycolysis is required to produce inflammatory cyto-
kines, such as interleukin (IL)-1β, in response to the Toll-like
receptor 4-ligand lipopolysaccharide (LPS)1,2. Pharmacological
inhibition of glycolysis induced, for instance, by the hexokinase
inhibitor 2-deoxyglucose (2-DG), results in a decrease of macro-
phage pro-inflammatory cytokine production3,4. Similarly, the
immunosuppressive cytokine IL-10 inhibits effector functions of
classically activated macrophages by decreasing glycolysis5. Con-
sistent with the impact on inflammatory response, glycolysis
inhibition offers protection in mouse models of experimental
endotoxemia and a large variety of immunopathologies3,4,6–8. The
increase of glycolytic flux is necessary to fulfill bioenergetic needs
of pro-inflammatory macrophages. Indeed, whereas resting and
alternatively activated macrophages predominantly generate ATP
via oxidative phosphorylation, LPS decreases mitochondrial oxy-
gen consumption, repurposing mitochondria from ATP synthesis
to reactive oxygen species (ROS) production, to promote a pro-
inflammatory state9. Beyond a rapid and robust ATP generation, a
high glycolytic rate also provides biosynthetic intermediates to
support macrophage effector functions. For instance, glucose fuels
the pentose phosphate pathway, necessary for maintenance of
redox homeostasis during inflammatory response2, as well as
sustains levels of the non-essential amino acid serine, whose de
novo synthesis supports LPS-induced IL-1β production10,11.
Importantly, glycolysis promotes IL-1β production also by sus-
taining succinate levels in pro-inflammatory macrophages3,9.
Succinate is a prototypical pro-inflammatory tricarboxylic acid
(TCA) cycle intermediate accumulating in macrophages in
response to LPS3,12–14. Such metabolite is also found
increased in fluids and tissues of individuals affected by a large
variety of immunopathologies, including chronic forms of intest-
inal inflammation, and has instrumental roles in their pathogen-
esis14–16. Mechanistically, succinate drives inflammatory signaling
by inducing stabilization of the hypoxia-inducible factor 1α (HIF-
1α), which, in turn, leads to up-regulation of IL1b gene
transcription3,9. Beyond acting as a direct inhibitor of prolyl
hydroxylases, which prime HIF-1α for proteasomal degradation,
succinate may also contribute to stabilize HIF-1α by sustaining
production of mitochondrial ROS through a reverse flow
of electron transfer across respiratory complexes, in pro-
inflammatory macrophages9. In line with its role in macrophage
activation, myeloid deletion of Hif1a gene results in a decreased
production of pro-inflammatory mediators and extended survival
in endotoxemic mice4,17. Overall, this body of knowledge indicates
that interventions aimed at tuning glucose utilization as well as
accumulation and bioactivity of succinate in inflammatory cells
might offer improved clinical benefit in immunopathology.
D-Mannose (hereafter referred to as mannose) is a natural C-2
epimer of glucose. It is transported into mammalian cells via
plasma membrane facilitated diffusion glucose transporters
(GLUT) and, within the cell, it is phosphorylated by hexokinase to
produce mannose-6-phosphate, which may undergo two major
metabolic fates. A minor fraction is isomerized to mannose
-1-phosphate by phosphomannomutase, to be directed into glyco-
sylation pathways. The large majority (~95%), instead, is converted to
fructose-6-phophate by phosphomannose isomerase (MPI), to be
catabolized into glycolysis. However, as physiological mannose con-
centration in human blood (~50 μM) is one-hundredth of that of
glucose, it does not contribute significantly to cell bioenergetics18.
Mannose supplementation, at safe supraphysiological doses, was
shown to ameliorate some human disease states. It is therapeutically
effective as a non-antibiotic treatment for recurrent urinary tract
infections in humans, by preventing adhesion of enteric bacteria to
uroepithelial cells18,19. Mannose was also demonstrated to affect T
cell function by promoting generation of regulatory T cells (Tregs)
from naive CD4+ T lymphocytes and, in such a way, suppressing T
cell-mediated experimental immunopathologies in mice20. More
recently, we reported that oral administration of mannose in mice is
effective in decreasing in vivo growth of multiple tumor types and
in potentiating the effects of cytotoxic chemotherapies21. In parti-
cular, MPI activity dictates sensitivity of tumors to the anti-
proliferative effects of such sugar. Cancer cells with low MPI levels
are unable to catabolize efficiently mannose-6-phosphate, which
accumulates intracellularly and impairs glucose utilization21. Cur-
rently, it is not known whether mannose metabolism affects func-
tion of glucose-addicted non-proliferating cells, such as
inflammatory macrophages.
Here, we demonstrate that mannose opposes LPS-induced
macrophage activation by impairing Il1b gene expression. Such
effect results from inhibition of glucose metabolism and sup-
pression of succinate-mediated HIF-1α activation. Moreover, we
identify MPI as the metabolic gatekeeper dictating response of
macrophages to the anti-inflammatory effects of mannose and
provide evidence for the utilization of such sugar to ameliorate
progression of ulcerative colitis in mice, by exploiting its cap-
ability to impair pro-inflammatory metabolic activation of
myeloid cells.
Results
Mannose opposes macrophage activation by impairing IL-1β
production. Glucose metabolism drives pro-inflammatory
cytokine IL-1β production in macrophages. To determine
whether mannose also has a role in macrophage activation, we
treated mouse bone marrow-derived macrophages (BMDMs)
with LPS for 24 h in culture media supplemented with different
concentrations of mannose. Such sugar decreased LPS-induced
Il1b gene expression dose dependently (Fig. 1a and Supple-
mentary Fig. 1A). In particular, a minimal dose of mannose
equimolar to that of glucose present in culture media was found
to be effective in dampening gene expression (Fig. 1a and
Supplementary Fig. 1A) and production of IL-1β (Fig. 1b) upon
LPS stimulation, preserving BMDMs viability (Supplementary
Fig. 1B). It is noteworthy that mannose halved LPS-induced
secretion of IL-1β independently on exposure of BMDMs to an
inflammasome assembly stimulus (ATP) (Fig. 1b). In line with
such result, no major direct impact of mannose on caspase-1
activity was detected upon ATP-dependent inflammasome
activation in LPS-stimulated BMDMs (Supplementary Fig. 1C),
indicating that mannose opposes IL-1β production mainly by
altering Il1b gene expression, rather than affecting pro-IL1β
processing. Interestingly, LPS-induced Il1b gene expression was
not reduced when mannose was replaced with equimolar con-
centrations of another monosaccharide, such as glucose or
fructose, or mannitol, a mannose derivative not metabolized in
animals (Supplementary Fig. 1D). Comparatively to Il1b,
mannose induced a small decrease in Tnf and Il6 genes
expression (Supplementary Fig. 1E) and did not elicit major
changes in anti-inflammatory cytokines transcription (Supple-
mentary Fig. 1F) in LPS-stimulated BMDMs. Similar effects on
pro-inflammatory cytokine profile were also observed in
BMDMs generated from a different mouse strain (Balb/c)
(Supplementary Fig. 1G), RAW 264.7 murine macrophage cell
line (Supplementary Fig. 1H) as well as human macrophages
derived from peripheral blood monocytes (Supplementary
Fig. 1I, J). Collectively, these data indicate that mannose
opposes classical macrophage activation by limiting, pre-
ferentially, optimal IL-1β production.
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Prompted by these data, we investigated whether mannose had
an in inhibitory effect on the systemic pro-inflammatory response
to LPS in vivo. Administration of 2 g/kg mannose in mice, given
hourly via intraperitoneal injections, resulted in a blood mannose
concentration of ~6.8–9.5 mM (Supplementary Fig. 2A) and was
effective in decreasing serum levels of IL-1β in mice challenged
with a single lethal dose of LPS (Fig. 1c). Importantly, mannose
treatment did not change weight of unstimulated mice (Supple-
mentary Fig. 2B), nor did it obviously affect their normal
behavior and health. However, it significantly prolonged survival
rate of LPS-treated mice (Fig. 1d). Overall, these data indicate that
well tolerated mannose administration regimen offers protection
from experimental lethal endotoxemia, associated with decreased
systemic IL-1β release.
Mannose impairs glucose utilization and succinate-mediated
HIF-1α activation. Next, we investigated the mechanisms by
which mannose impairs LPS-induced IL-1β production. The
mannose receptor (MRC1) is a C-type lectin expressed in pha-
gocytes capable to bind microbial glycoligands containing
exposed mannose or other sugar residues22. As MRC1 might play
important roles in control of inflammation, we measured the
extent to which it contributes to mannose-mediated suppression
of IL1β production. Silencing MRC1 expression, achieved by
transducing BMDMs with two independent short hairpin RNAs
(shRNAs) (Supplementary Fig. 3A, B), did not abolish the relative
ability of mannose treatment to decrease IL1β production in LPS-
stimulated macrophages (Supplementary Fig. 3C), suggesting that
mannose opposes IL-1β production primarily via an MRC1-
independent manner.
We have recently demonstrated that mannose decreases
proliferative capacity of cancer cells by inhibiting glycolysis21.
Interestingly, mannose was found to be more effective in
inhibiting Il1b expression in BMDMs cultured in a medium
containing low glucose (5.5 mM) compared with a medium with
standard (higher) glucose concentration (11 mM) (Fig. 1a and
Supplementary Fig. 1A), suggesting that it might control Il1b
IL
-1
 
m
R
N
A
 (
fo
ld
 c
ha
ng
e)
(c
om
pa
re
d 
w
ith
ve
hi
cl
e-
tr
ea
te
d 
LP
S
-s
tim
ul
at
ed
 B
M
D
M
s)
S
ec
re
te
d
 IL
-1
 
(p
g/
m
l)
M
ic
e 
su
rv
iv
al
 (
%
)
IL
-1
 
(p
g/
m
l)
1.5
a b
c d300
200
100
0
600
400
200
0
100
75
50
25
0
Vehicle
Mannose
P = 0.0085
P = 0.0016
Vehicle
Mannose Vehicle
Mannose
Vehicle
– ATP + ATP
Mannose
1.0
0.5
0.0
–
–
– + – +
+
–5.5 11 25 5.5 11 25Mannose
LPS
– +LPS
LPS
Time (h)
0 6 12 18
Fig. 1 Mannose impairs LPS-induced IL-1β production. a qPCR analysis of IL-1β mRNA levels in resting and LPS-activated BMDMs cultured for 24 h in the
presence or absence of the indicated concentrations of mannose in RPMI medium containing 11 mM glucose. Data are presented as mean ± s.e.m. of at
least n= 6 wells pooled from two independent experiments performed in technical triplicate. In this and all other figures, “wells” represent technical
replicate samples setup and assessed under identical conditions within a single experiment. ***P < 0.001 (two-tailed Student’s t-test). b ELISA-mediated
determination of IL-1β secreted in media of BMDMs treated as in a. When indicated (+ATP), BMDMs were incubated with 2.5 mM ATP for additional 40
min for inflammasome activation. Data are presented as mean ± s.e.m. of n= 10 wells pooled from two independent experiments. ***P < 0.001 (two-tailed
Student’s t-test). c, d Endotoxin-induced model of sepsis. Seven- to 9-week-aged male Balb/c mice were stimulated with a single intraperitoneal (i.p)
injection of 20mg/kg O55:B5 LPS and treated with either 2 g/kg mannose or saline control (vehicle) solution given hourly by i.p. injections for up to six
times. In c mice were sacrificed after 3 h and IL-1β concentration in serum determined by ELISA. Data are presented as box plot of n= 18 (vehicle-treated
LPS-stimulated), n= 20 (mannose-treated LPS-stimulated) and n= 6 (LPS untreated) mice. Boxes extend from the 25th to 75th percentiles, bold black line
indicates median, and the whiskers range from the minimum to maximum value. In d, survival of n= 13 LPS-stimulated mice per group, treated as in c, was
monitored up to 18 h. Indicated P value in c and in d were calculated by two-tailed Student’s t-test and log-rank (Mantel–Cox) test, respectively. Source
data are provided as a Source Data file.
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expression in LPS-activated macrophages by affecting glucose
metabolism. Therefore, prompted by such results, we determined
directly whether mannose had impact on macrophage glucose
metabolism by stimulating BMDMs with LPS for 24 h in the
presence or absence of uniformly labeled U-13C6-mannose in the
culture medium, in order to distinguish metabolites containing
mannose carbons from those derived from glucose, by molecular
mass. Liquid chromatography-mass spectrometry (LC-MS)
analysis indicated that mannose treatment opposes the increase
of glycolytic rate induced by pro-inflammatory stimulation in
macrophages, as shown by the decreased lactate secretion in LPS-
activated BMDMs incubated with mannose, with respect to
mannose-untreated counterparts (Fig. 2a). Moreover, compared
with glucose, mannose is less efficiently metabolized through
glycolysis in macrophages, as evidenced by the lower fractional
secretion rate of lactate pool derived from mannose (13C3-
lactate), with respect to that produced from glucose (12C-lactate),
in mannose-treated BMDMs (Fig. 2a), and accumulates intra-
cellularly as mannose-6-phosphate (Fig. 2b), whose levels are
further increased in inflammatory macrophages, reasonably as a
result of higher mannose uptake rate detected in in response to
LPS (Supplementary Fig. 4A). Mannose-6-phosphate is known to
act as an inhibitor of some apical glycolytic enzymes, such as
hexokinase and phosphoglucose isomerase23. Therefore, to
elucidate the impact of mannose on glucose metabolism in
macrophages, we traced the intracellular fate of glucose carbons
in BMDMs cultured in a medium containing uniformly labeled
U-13C6-glucose. LC-MS-mediated deconvolution of glycolytic
intermediates revealed that mannose treatment mainly hampers
glucose phosphorylation rather than its uptake in macrophages,
as indicated by the increase in intracellular 13C6-glucose
abundance and concomitant decrease in the levels of 13C6-
glucose-6-phosphate in mannose-treated BMDMs, compared
with mannose-untreated counterparts (Fig. 2d). As a result of
such alteration, mannose supplementation significantly decreased
the intracellular abundance of representative glucose-derived
glycolytic metabolites downstream glucose-6-phosphate (Fig. 2d),
and resulted in a drop of glucose consumption rate (Fig. 2e). In
line with the reduction of the overall glycolytic flux, a significant
attenuation of ATP levels was measured in LPS-activated
BMDMs incubated with mannose, with respect to mannose-
untreated macrophages (Supplementary Fig. 4B). In line with
such metabolic changes, incubation of BMDMs with the down-
stream glycolysis intermediate pyruvate, provided in the form of
its cell-permeable analog methyl-pyruvate, repressed substantially
the capability of mannose to oppose IL-1β production upon LPS
exposure (Supplementary Fig. 4C), indicating that the impair-
ment of glycolytic route is instrumental for the effects of mannose
treatment on macrophage activation.
Glucose is a key carbon source for the TCA cycle, which acts as
a metabolic platform for inflammatory signaling in macro-
phages24. Consistent with the decreased utilization of glucose in
glycolysis, mannose treatment reduced also the entry of glucose-
derived carbons into the TCA cycle, as demonstrated by the
considerable suppression of 13C labeling pattern of several TCA
cycle metabolites both in mannose-treated resting and LPS-
stimulated BMDMs cultured in U-13C6-glucose-containing med-
ium, with respect to mannose-untreated counterparts (Fig. 2e and
Supplementary Fig. 4D, E). Suppression of glucose catabolism is
known to decrease succinate abundance in inflammatory
macrophages3. Consistent with this, the diminished glucose-
dependent TCA cycle anaplerosis was associated with a
substantial attenuation of succinate levels accumulating in
BMDMs in response to LPS exposure (Fig. 2e). Succinate sustains
IL-1β production by promoting HIF-1α stabilization in pro-
inflammatory macrophages3,9. Therefore, we envisioned that
reduced succinate abundance imposed by mannose upon LPS
exposure might underlie the impact of such sugar on BMDMs
activation. To test this hypothesis, we assessed the effect of
mannose on Il1b expression in macrophages cultured in a
medium supplemented with succinate in the form of its cell-
permeable analog diethyl-succinate3,9. As expected, diethyl-
succinate increased LPS-induced Il1b expression in BMDMs
and, importantly, repressed significantly the capability of
mannose to impair Il1b expression, upon LPS exposure (Fig. 2f).
In line with such changes, diethyl-succinate rescued the levels of
succinate in LPS-stimulated BMDMs treated with mannose
(Supplementary Fig. 4F) but did not elicit significant changes in
steady-state levels of fumarate and α-ketoglutarate (Supplemen-
tary Fig. 4F), two TCA cycle metabolites playing a role in
regulating macrophage response to LPS24, thus indicating that the
impact of mannose on succinate accumulation is instrumental for
opposing macrophage activation. This result prompted us to
investigate the effect of mannose on succinate-dependent HIF-1α
activation in response to LPS. In line with the effects on succinate
accumulation, mannose treatment decreased HIF-1α levels,
measured by western blotting, in mouse and human derived
macrophages activated by LPS in vitro (Fig. 2g and Supplemen-
tary Fig. 5A) as well as in peritoneal macrophages isolated from
mice challenged with LPS (Supplementary Fig. 5B). The effects of
mannose treatment on HIF-1α activation was abrogated when
BMDMs were incubated with diethyl-succinate (Supplementary
Fig. 5C), indicating that mannose impairs LPS-induced HIF-1α
activation mainly by decreasing succinate abundance in macro-
phages. Next, we determined the extent to which the impairment
of HIF-1α activation contributes to mannose-mediated suppres-
sion of Il1b expression. For this aim Hif1a expression was
silenced by transducing BMDMs with two independent shRNAs
(Supplementary Fig. 5D). As expected, decreased Il1b expression
was detected in HIF-1α-silenced macrophages, with respect to
HIF-1α-expressing counterparts, upon LPS exposure (Supple-
mentary Fig. 5E). Importantly, Hif1a silencing abolished the
ability of mannose to further affect Il1b expression (Supplemen-
tary Fig. 5E), indicating that the impairment of HIF-1α activation
is a response to mannose instrumental for dampening Il1b
expression. Overall, these data demonstrate that mannose
decreases glucose catabolism in macrophages and impairs
succinate-mediated HIF-1α activation, thus reducing LPS-
induced Il1b expression (Fig. 2h).
MPI dictates response of LPS-activated macrophages to man-
nose. Next we explored the molecular determinants of macro-
phage sensitivity to mannose. We have recently demonstrated
that MPI, apical enzyme in the mannose catabolic pathway
(Fig. 2h), opposes the anti-tumor effects of such sugar, by pre-
venting mannose-6-phosphate accumulation in cancer cells21.
Prompted by this knowledge, we measured MPI enzymatic
activity in cultured macrophages. We found that it did not change
substantially in BMDMs in response to LPS treatment (Fig. 3a).
However, its extent, measured both in resting and LPS-activated
BMDMs, was much lower than that determined in previously
reported mannose-insensitive cell lines (SKOV3 and RKO) and
comparable to that measured in mannose-sensitive ones (SAOS2
and U2OS)21 (Fig. 3a), suggesting a pivotal role for MPI in
priming macrophages to the anti-inflammatory effect of man-
nose. To test this hypothesis, BMDMs were transduced with a
lentiviral vector expressing mouse Mpi cDNA (Supplementary
Fig. 6A) and metabolically assessed upon LPS exposure. As
expected, MPI overexpression decreased mannose-6-phosphate
levels accumulating in LPS-activated BMDMs upon U-13C6-
mannose incubation compared with the empty-vector transduced
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Fig. 2 Mannose impairs glucose utilization and succinate-mediated HIF-1α activation. a Lactate secretion rate measured in resting and LPS-activated
BMDMs cultured for 24 h in RPMI medium containing 11 mM glucose in the presence/absence of 11 mM U-13C6-Mannose. 12C-lactate and 13C3-lactate
were used were used as identifiers of glucose (Gluc-derived) and mannose-derived (Mann-derived) lactate, respectively. Data are presented as mean ±
s.e.m. of n= 6 wells pooled from two independent experiments. b Intracellular levels of mannose-6-phosphate (13C6-mannose-6-phosphate) measured in
BMDMs cultured for 24 h in RPMI medium containing 11 mM glucose in the presence/absence of 11 mM U-13C6-mannose. Data are presented as mean ±
s.e.m. of n= 4 wells from two independent experiments; nd not detectable. c Intracellular levels of the indicated metabolites in BMDMs cultured for 24 h in
RPMI medium containing 11 mM U-13C6-glucose in the presence/absence of 11 mM mannose. Data are presented as mean ± s.e.m. of n= 4 wells from two
independent experiments. 13C3-Glucose-6-P 13C3-Glucose-6-phosphate, 13C3-GA3-P 13C3-glyceraldehyde-3-phosphate, nd not detectable. d Glucose
consumption rate in BMDMs cultured for 24 h as in b. Data are presented as mean ± s.e.m. of n= 6 wells pooled from two independent experiments.
e Intracellular succinate levels in BMDMs cultured for 24 h RPMI medium containing in 11 mM U-13C6-Glucose in the presence/absence of 11 mM
mannose. The abundance of all succinate isotopologues is reported. Data are presented as mean ± s.e.m. of n= 4 wells from two independent experiments.
f Effect of 5 mM diethyl-succinate treatment in BMDMs on IL-1β mRNA levels measured in BMDMs cultured for 24 h in medium containing in 11 mM
glucose in the presence/absence of 11 mM mannose. Data are presented as mean ± s.e.m. of n= 6 wells pooled from two independent experiments
performed in technical triplicate. g Representative image of HIF-1α of two independent experiments in BMDMs cultured for 24 h in RPMI medium
containing 11 mM glucose in the presence/absence of 11 mM mannose. β-Actin was used as a loading control. h Representation of glycolysis, TCA cycle,
reactions metabolizing mannose into glycolysis and regulation of Il1b expression by succinate-mediated HIF-1α activation. HK hexokinase, MPI
phosphomannose isomerase. In a, d, f *P < 0.05, **P < 0.01 and ***P < 0.001 (two-tailed Student’s t-test). Source data are provided as a Source Data file.
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counterparts (Supplementary Fig. 6B). As a result of mannose-6-
phosphate clearance, increased MPI levels abrogated the impact
of mannose on glucose utilization in LPS-activated BMDMs, as
indicated by the significant restoration of intracellular glucose-6-
phospate abundance (Supplementary Fig. 6C) as well as both
overall and glucose-derived lactate (12C-lactate) levels (Supple-
mentary Fig. 6D), used as proxy for glycolytic activity in mac-
rophages. Importantly, MPI overexpression rescued also the effect
of LPS on succinate accumulation in mannose-treated BMDMs
(Fig. 3b). Consistent with this, restoration of both LPS-induced
HIF-1α activation (Fig. 3c) and Il1b gene expression (Fig. 3d)
were observed in MPI-transduced BMDMs treated with mannose,
compared with empty-vector-transduced counterparts. To cor-
roborate the role of MPI in determining sensitivity of macro-
phages to mannose, we silenced Mpi expression by transducing
BMDMs with two independent shRNAs (Supplementary Fig. 6E).
Strikingly, suppression of Mpi gene expression potentiated the
impact of sub-effective doses of mannose on intracellular accu-
mulation of lactate (Supplementary Fig. 6F) and succinate
(Fig. 3e) as well as IL-1β production induced by LPS exposure in
BMDMs (Fig. 3f). Furthermore, contrarily to MPI silencing,
overexpression of phosphomannomutase, achieved by transdu-
cing BMDMs with a lentiviral vector expressing mouse Pmm2
cDNA (Supplementary Fig. 6F), did not enhance the impact of
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sub-effective mannose concentrations on IL-1β production in LPS-
activated macrophages (Supplementary Fig. 6H). Overall, such
results indicate that, contrarily to the phosphomannomutase-
regulated pathway, MPI plays an instrumental role in determin-
ing response of pro-inflammatory macrophages to mannose.
Mannose protects mice from DSS-induced ulcerative colitis.
Aberrant activation of pro-inflammatory myeloid cells and sus-
tained production of inflammatory cytokines, such as IL-1β, play
instrumental role in the pathogenesis of inflammatory bowel
diseases, such as ulcerative colitis and Crohn’s Disease25–28.
Therefore, to further explore the impact of mannose on inflam-
matory response in vivo, we evaluated the preventive effects of
such sugar on the progression of colitis induced by dextran sulfate
sodium (DSS) in mice. Administration of supraphysiological doses
of mannose via oral gavage had no major impacts on healthy mice.
However, it opposed loss of body weight induced by DSS treat-
ment (Fig. 4a) and delayed colitis progression (Fig. 4b), as indi-
cated by the improvement of stools consistency (Supplementary
Fig. 7A), attenuation of colorectal bleeding (Supplementary
Fig. 7B) and counteraction of colon shortening (Fig. 4c and
Supplementary Fig. 7C). In line with these data, qualitative
(Fig. 4d) and quantitative (Supplementary Fig. 7D) histological
examination of colon morphology revealed a marked decrease in
the extent of epithelial disruption, crypt damage, and submucosal
infiltration of inflammatory cells in colon of DSS-treated mice in
response to mannose administration. In support of these obser-
vations, higher accumulation of myeloid (CD11b+) cells was
detected by flow cytometry in colon lamina propria (LP) of DSS-
treated mice compared with mannose-treated counterparts
(Fig. 4e and Supplementary Fig. 8A). In contrast, colitis ameli-
oration was not associated with changes in number of immuno-
suppressive Tregs accumulating in mice colon in response to DSS
exposure (Supplementary Fig. 7E and Supplementary Fig. 8B). In
addition to the preventive administration schedule, a delayed
mannose treatment regimen (Supplementary Fig. 9A) was found
to offer some anti-colitis therapeutic efficacy, as well. Indeed, oral
administration of mannose after the onset of clinical signs of
chemical-induced colitis, such as production of soft stools or the
appearance of occult blood in feces, resulted in diminished pro-
portions of DSS-treated mice showing severe colorectal bleeding
and diarrhea compared with vehicle-treated counterparts (Sup-
plementary Fig. 9B). Furthermore, mannose-treated mice showed
longer colon length (Supplementary Fig. 9C) as well as decreased
extent of colonic tissue damage and submucosal immune cell
infiltration (Supplementary Fig. 9D) compared with the vehicle-
treated group in response to DSS challenge.
Results obtained from such experiments prompted us to
investigate the effects of mannose administration on metabolic
activation of CD11b+ cells immunomagnetically isolated
from colon submucosa of DSS-treated mice. Similarly to the
impact on LPS-activated macrophages in vitro, mannose
attenuated lactate (Fig. 4f) and succinate (Fig. 4g) levels
increasing in CD11b+ cells infiltrating mice colon in response
to DSS exposure. In line with such metabolic changes, lower Il1b
expression was detected in such cells with respect to the myeloid
counterparts isolated from the DSS-treated control group
(Fig. 4h). It is noteworthy that mannose dampened the levels
of HIF-1α increasing in CD11b+ cells in response to DSS
challenge (Supplementary Fig. 7F), without eliciting major
changes on its abundance in intestinal epithelial barrier cells of
colitic mice (Supplementary Fig. 7G). Overall, these data indicate
that mannose opposes metabolic changes supporting the
engagement of pro-inflammatory signaling in colonic myeloid
cells, resulting in colitis amelioration.
Discussion
Macrophages are a main component of innate immunity playing
a crucial role in promotion of inflammation in defence against
pathogens. However, continuous production of pro-inflammatory
mediators, resulting either from severe systemic reaction to
infection (sepsis) or from unresolved responses to chronic tissue-
damaging conditions, as those occurring in inflammatory bowel
diseases, might be harmful and even lethal. Changes in nutrients
utilization and metabolic fluxes drive malignant transformation
and play instrumental roles in dictating cell fate and effector
functions in immunity1,29. Therefore, interventions altering
metabolic reprogramming in cancer as well as immune cells
might offer valuable therapeutic options in both cancer and
immunopathology8,24. Glucose is an essential nutrient both for
neoplastic cells and pro-inflammatory macrophages. However,
whereas glucose carbons are required for generation of novel
biomass supporting proliferation of cancer cells, Warburg-like
enhancement of glucose metabolism drives production of
inflammatory cytokines, such as IL-1β, in classically activated
macrophages2,4,30. In line with this, the hexokinase inhibitor 2-
DG is known to impair LPS-induced IL-1β production in
BMDMs3. Similarly, inhibition of glycolytic enzymes, such as
glyceraldehyde-3-phosphate dehydrogenase and aldolase A, sub-
stantially accounts for the anti-inflammatory effects elicited by
the immunosuppressive metabolite itaconate31,32 and synthetic
analogs of fumarate in macrophages6. Overall, these findings
clearly emphasized the therapeutic value of targeting glucose
metabolism for successful treatment of inflammatory diseases.
Whereas the role of glucose in cancer and immune cells has
been extensively investigated, the impact of different sugars on
tumor growth and control of immune functions remains largely
unexplored. We have recently demonstrated that the mono-
saccharide mannose inhibits growth of several forms of tumors by
antagonizing glucose utilization of cancer cells6. Here, we report
that mannose opposes classical macrophages activation by
impairing LPS-induced Il1b gene expression. By employing stable
isotope labeling techniques, we found that such phenotypic effect
results from a diminished glucose metabolism in macrophages
and a decreased LPS-induced succinate accumulation. Succinate
is a prototypical inflammatory TCA cycle metabolite accumu-
lating in pro-inflammatory macrophages to drive IL-1β produc-
tion, by stabilizing the Il1b gene transcription factor HIF-1α3,4.
Importantly, glycolysis inhibition is known to decrease succinate
levels and to impair HIF-1α-dependent Il1b expression in LPS-
activated macrophages3. Similarly, by silencing HIF-1α levels in
BMDMs, here we provide evidence for the occurrence of an
epistatic relationship between suppression of LPS-induced HIF-1α
activation and impairment of Il1b expression in mannose-treated
macrophages. Furthermore, rescuing both HIF-1α activation and
Il1b expression, by supplementing mannose-treated BMDMs with a
cell-permeable form of succinate, we demonstrated that the impact
of mannose on succinate pool of LPS-activated macrophages is
instrumental for impairing HIF-1α activation and optimal Il1b
expression. Importantly, in line with the suppression of macrophage
activation, pharmacological inhibition of glycolysis and genetic
ablation of HIF-1α in myeloid cells are known to offer protection
against septic shock in mice3,4,33. Likewise, here we demonstrate
that administration of mannose decreases serum levels of IL-1β,
accumulation of HIF-1α in peritoneal macrophages, and lethality in
endotoxemic mice.
Mannose is a natural C-2 epimer of glucose. It is internalized in
cells through GLUT transporters and then phosphorylated to
mannose-6-phosphate by hexokinases. A minor fraction of such
metabolite can be directed into glycosylation pathways; the
majority of mannose-6-phosphate pool is catabolized into gly-
colysis after conversion to fructose-6-phophate in a reaction
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Fig. 4 Mannose protects mice from DSS-induced ulcerative colitis. a Seven-week-aged C57BL/6 mice were pre-treated for 2 weeks with or without 20%
(w/v) mannose given in drinking water. At the end of the pre-treatment, 3% (w/v) DSS in drinking water was administered ad libitum over a 7-day period.
During DSS administration, mice were treated with 200 µl of either water or 20% (w/v) mannose by oral gavage twice a day. Body weights were
determined daily and compared to the weights at the start of DSS treatment for each mouse. b Effect of mannose on disease activity index measured daily
in mice described in a during DSS treatment schedule. In a, b, *P < 0.05; ***P < 0.001 (two-tailed Student’s t-test) compared with mannose-untreated DSS-
administered mice. c Colon length of mice described in a. In a–c data are presented as mean ± s.e.m. of at least n= 16 (DSS-treated) and n= 12 (DSS-
untreated) mice pooled from two independent experiments. d Representative H&E-stained images, out of three independently acquired, of colon sections
from the indicated groups of mice treated as in a at the end of DSS administration (scale bar 200 µm). e FACS-mediated analysis of CD11b+ immune cell
types infiltrating colon lamina propria of DSS-administered mice in response to mannose treatment, as described in a, at the end of the experiment. Data
are presented as mean ± s.e.m. of n= 13 (H2O-treated) and n= 12 (mannose-treated) mice from two independent experiments. LC-MS-mediated analysis
of lactate (f) and succinate (g) levels in CD11b+ cells isolated from colon lamina propria of mice treated as in a at the end of DSS administration. Data are
presented as mean ± s.d. of n= 6 (DSS-treated) and n= 3 (DSS-untreated) mice. h qPCR analysis of IL-1β mRNA levels in CD11b+ cells isolated from colon
lamina propria of mice treated as in a at the end of DSS administration. Data are presented as mean ± s.d. of n= 7 (DSS-challenged vehicle-treated), n= 8
(DSS-challenged mannose-treated) assessed in technical triplicate each and and n= 2 (DSS-untreated) mice assessed at least in technical duplicate each.
In c, e–h, *P < 0.05; **P < 0.01; ***P < 0.001 (two-tailed Student’s t-test). Source data are provided as a Source Data file.
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catalyzed by MPI18. We have recently demonstrated that cancer
cells expressing low MPI levels inefficiently catabolizes mannose-
6-phosphate which, accumulating intracellularly, inhibits glucose
oxidation21. Similarly, here we show that mannose-6-phosphate
levels increase in BMDMs in response to mannose and LPS
treatments, resulting in a concomitant impairment of glucose
catabolism. Importantly, we identified MPI as the molecular
determinant dictating sensitivity of macrophages to such sugar.
Indeed, MPI activity in BMDMs was found of comparable extent
to that measured in previously identified mannose-sensitive
cancer cells21. Furthermore, MPI overexpression totally abolished
the impact of mannose on glucose utilization and rescued the
engagement of HIF-1α signaling pathway supporting Il1b gene
expression in LPS-activated BMDMs. Suppression of MPI
expression potentiates the anti-proliferative effects of mannose on
cancer cells21. Similarly, we found that Mpi silencing in BMDMs
enhanced the impact of sub-effective mannose concentrations on
LPS-induced IL-1β production. Importantly, beyond contributing
to further understanding the mechanism of action underlying the
anti-inflammatory effect of mannose, such in vitro observation
might pave the way for preclinical testing of pharmacological
MPI inhibitors in combination with mannose for potential
treatment of inflammatory diseases.
Mannose was demonstrated to induce the generation of Tregs
from naive CD4+ T cells. This effect underlies the capability of
orally given mannose to suppress T cell-mediated immuno-
pathology in mice, such as autoimmune type 1 diabetes and
antigen-specific lung airway inflammation20. Here, we provide
evidence for the utilization of mannose to ameliorate ulcerative
colitis in mice. DSS-induced colitis has been extensively used as a
preclinical model for investigating the instrumental contribution
of myeloid cell activation to the progression of lethal intestinal
inflammation in mice, in order to identify effective therapeutic
strategies against inflammatory bowel diseases in humans34. We
found that mannose decreased the number and activation of pro-
inflammatory myeloid cells infiltrating colons of DSS-treated mice
and to oppose HIF-1α activation, consistent with the role of
myeloid HIF-1α activation in promoting DSS-induced colitis
progression35,36. However, although similar treatment regimens
were effective in increasing the frequency of immunosuppressive
Tregs in lymphoid organs and pancreases of autoimmune diabetic
mice20, mannose-induced colitis amelioration was not associated
with changes in number of Tregs infiltrating mice colons in
response to DSS challenge (Supplementary Fig. 7E). Importantly,
analogously to the metabolic effects observed in LPS-activated
macrophages cultured in vitro, we found that mannose treatment
was effective in opposing the accumulation of lactate and succi-
nate, supporting pro-inflammatory HIF-1α signaling activation in
CD11b+-infiltrating colons of DSS-treated mice. Beyond provid-
ing mechanistic understanding of the anticolitic effects of man-
nose in vivo, our data support the potential utilization of glycolytic
inhibitors (i.e. 2-DG) having metabolic effects similar to mannose
on inflammatory myeloid cells, in order to counteract progression
of ulcerative colitis. Furthermore, it is noteworthy that changes in
colon microbiota contribute to colitis pathogenesis37,38. Mannose
has been recently demonstrated to counteract high-fat diet-
induced obesity in mice by altering gut microbial composition39.
Therefore, future investigations, beyond the aim of the present
work, are foreseen to determine whether, and the extent to which,
restoration of colon dysbiosis, induced by mannose administration
in mice, might contribute to colitis amelioration.
In summary, this study has uncovered, functionally and
mechanistically, an unrecognized impact of sugar metabolism on
pro-inflammatory macrophage activation, paving the way for a
novel, safe and effective metabolic intervention against intestinal
inflammation.
Methods
Cell lines and reagents. HEK293T, SKOV3, RKO, SAOS2, and U2OS cells (from
ATCC) were maintained in DMEM (10313021 Thermo Fisher Scientific) con-
taining 25 mM glucose supplemented with 10% FBS and 2mM L-glutamine.
Sources of reagents used in this study are indicated throughout the following
sections. All reagents not described here were obtained from Sigma-Aldrich.
Generation of BMDMs. If not otherwise stated throughout the main text or in
each figure caption, bone marrow (BM)-derived macrophages (BMDMs) were
prepared from 7- to 9-week-old CO2-euthanized C57BL/6N female mice and
subjected to red blood cell lysis with ACK lysis buffer prior to neutralization in
phosphate-buffered saline (PBS). BM was seeded at 3 × 105 cells/well in six-well
tissue-culture plates and differentiated in IMDM medium (Thermo Fisher Scien-
tific) containing 25 mM glucose supplemented with 10% FBS (Gibco), 2 mM L-L-
glutamine (Thermo Fisher Scientific) in the presence of 20 ng/ml recombinant
mouse M-CSF (576404, Biolegend) for 7 days. When BMDMs from Balb/c back-
ground were used, they were generated analogously to C57BL/6N ones.
Generation of human macrophages from peripheral blood monocytes. Per-
ipheral blood mononuclear cells (PBMCs) were isolated from blood samples of
healthy donors centrifuged on a FICOLL (Histopaque®-1077, Sigma-Aldrich
10771) density gradient at 400g for 40 min. CD14+ monocytes were then purified
from the PBMCs by magnetic-activated cell sorting using human CD14
MicroBeads (130-050-201, Miltenyi Biotech). CD14+ monocytes were seeded at
3 × 105 cells/well in six-well tissue-culture plates and differentiated in DMEM
medium (D6546, Thermo Fisher Scientific) containing 25 mM glucose supple-
mented with 10% FBS (Gibco), 2 mM L-L-glutamine (Thermo Fisher Scientific) in
the presence of 50 ng/ml recombinant human M-CSF (Biolegend) for 7 days.
Human peripheral blood was collected upon informed consent from healthy
volunteers according to the Institutional Ethical Committee approved protocol
(TIGET09) and with the Declaration of Helsinki.
Treatments. At the end of the differentiation, BMDMs and human macrophages
were washed with PBS and used for in vitro treatments performed, respectively, in
RPMI 1640 (R0883, Thermo Fisher Scientific, containing 11 mM glucose), DMEM
(D5921, Thermo Fisher Scientific, containing 5.5 mM glucose) media, both sup-
plemented with 10% FBS and 2mM L-glutamine (Thermo Fisher Scientific). RAW
264.7 cells (from ATCC) were treated in DMEM medium (D5671, Thermo Fisher
Scientific, containing 25 mM glucose) supplemented with 10% FBS and 2 mM
L-glutamine. BMDMs, human macrophages, and RAW 264.7 cells were activated
with 100 ng/ml LPS (Enzo Life Sciences) diluted in water for 24 h. Where used
in vitro, D-mannose (M8574, Sigma-Aldrich) was solubilized in water and added at
concentrations equimolar to that of glucose present in culture media, 2 h before
LPS treatment, if not otherwise indicated. As control, mannose and/or LPS-
untreated cells were incubated with corresponding volumes of water (vehicle).
Diethyl-succinate and methyl-pyruvate were used at the concentrations indicated
in each figure caption and incubated 2 h before LPS treatment.
Measurement of cell viability. Cell viability was determined by 0.4% Trypan Blue
dye exclusion test executed by the LUNA-IITM Automated Cell Counter (Logos
Biosystems).
RNA extraction and real-time qPCR. RNA was extracted by TRIzol™ Reagent
(15596018, Thermo Fisher Scientific) according to the manufacturer’s instructions.
For real-time qPCR analysis, 1 μg of total RNA was retro-transcribed into com-
plementary DNA using SuperScript VILO reverse transcriptase (11755-050, Invi-
trogen). cDNAs were mixed with PowerUp™ SYBR™ Green Master Mix (A25742,
Applied Biosystems) according to the manufacturer’s instructions and 4 pmol of
both forward and reverse primers for detecting mRNA levels of mouse and human
genes. A complete list of all primers used, including the names and sequences, is
supplied as Supplementary Table 1. qPCR was carried out using a 7500 fast real-
time PCR system (Applied Biosystems) and the amplification steps were 95 °C for
20 s, followed by 40 cycles of 95 °C for 3 s and 60 °C for 30 s. The relative quan-
tification of each mRNA was carried out with the comparative threshold cycle
method using ribosomal protein S18 (Rps18/RPS18) or β-actin (Actb) for nor-
malization of in vitro and in vivo studies, respectively.
Enzyme-linked immunosorbent assay (ELISA). IL-1β concentrations in BMDMs
and RAW 264.7 culture medium as well as mice serum was measured using IL-1
beta mouse-uncoated ELISA Kit (88701376, Invitrogen), according to the manu-
facturer’s instructions. For inflammasome activation, BMDMs were incubated with
2.5 mM ATP for 40 min after priming with LPS for 24 h. TNF and IL-6 levels were
determined in BMDMs and RAW 264.7 culture medium using, respectively, TNF
(88-7324-22 Invitrogen) and IL-6 mouse (88-7064-22) uncoated ELISA Kits
according to the manufacturer’s instructions. Absorbances were measured at a
wavelength of 450 nm, subtracting the values measured at 570 nm, using a
microplate reader (Bio-Rad).
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Measurement of Caspase-1 activity. For inflammasome activation, 4.5 × 104
BMDMs were incubated with 2.5 mM ATP for 40 min after priming with LPS for
24 h. Enzymatic activity of Caspase-1 was determined in BMDMs with the
Caspase-Glo® 1 Inflammasome Assay (Promega) according to the manufacturer’s
instructions. Luminescence was recorded by the Victor Multilabel Plate Reader.
Immunoblotting. Cells were washed twice with cold PBS and lysed in radio-
immunoprecipitation assay (RIPA) buffer supplemented with protease (cOmplete™
Mini EDTA-free Protease, Roche) and phosphatase (PhosSTOP EASYpack, Roche)
inhibitor cocktails. Protein concentration was determined with the BCA Protein
Assay Kit (23227, Pierce) using BSA as a standard. Equal amounts of protein were
mixed with reducing Laemmli 4× buffer, warmed at 95 °C for 5 min, and loaded on
8% gels for SDS-PAGE. After electrophoretic separation, proteins were blotted onto
0.45 mm nitrocellulose (Amersham Protran), blocked with 10% non-fat milk in
Tris-buffered saline-Tween, and incubated at 4 °C overnight with the following
antibodies: anti-HIF-1 alpha (rabbit polyclonal, Novus Biologicals NB100-499,
1:200 for mouse macrophages and mouse monoclonal, BD Biosciences 610958,
1:500 for human macrophages), anti-MPI (mouse monoclonal, Santa Cruz Bio-
technology sc-393477, 1:500), anti-Vinculin (mouse monoclonal, Sigma-Aldrich
SAB4200729, 1:5000), and anti-β-Actin (mouse monoclonal, Sigma-Aldrich,
A5441, 1:10000). Membranes were then washed and incubated with HRP-linked
anti-rabbit (NA934V, GE Healthcare) or anti-mouse (NA931V, GE Healthcare)
secondary antibodies at 1:10,000 dilution. Chemiluminescent signal was acquired
using a ChemiDocTM MP Imaging System (Bio-rad) after incubation with
Supersignal West Pico PLUS Chemiluminescent Substrate (34580, Thermo Fisher
Scientific).
Metabolite extraction and LC-MS. For 13C-glucose-tracing assays, BMDMs were
treated in glucose-free RPMI 1640 medium (11879, Thermo Fisher Scientific)
containing 2 mM L-glutamine, supplemented with 10% FBS and 11 mM U-13C6-D-
glucose (CLM-1396, Cambridge Isotopes Laboratories) in the presence or absence
of 11 mM unlabeled D-mannose for 24 h. For 13C-mannose-tracing assays and
extracellular (exo-) metabolites determination, BMDMs were treated in 10% FBS,
2 mM L-glutamine-supplemented RPMI 1640 medium (31870074, Thermo Fisher
Scientific) containing 11 mM unlabeled D-glucose in the presence or absence of
U-13C6-D-mannose (CLM-6567, Cambridge Isotopes Laboratories) for 24 h. At the
end of the treatments, monolayers were rapidly washed three times with ice-cold
PBS and extracted with 600 μl of ice-cold extraction solution, composed of
methanol, acetonitrile, and water (5:3:2), for endo-metabolite determination.
Alternatively, media were diluted 1:50 in extraction solution for exo-metabolites
analyses. Media derived from wells lacking cells but incubated in the same con-
ditions were used as a reference to quantify the exchange rate (consumption/
secretion) of exo-metabolites. To measure mannose concentration in blood, mouse
tail tipping was performed before the first intraperitoneal injection of 2 g/kg
mannose and 15 min after each (n= 3) administration, given hourly. Blood sam-
ples were then diluted in 250 µl of extraction solution (1:50 dilution). Culture
media, cells, and blood extracts were then centrifuged at 16,000g for 30 min at 4 °C
and the supernatants were analyzed by liquid chromatography-mass spectrometry
(LC-MS). Endo-metabolites and exchange rates were normalized to the protein
content in each well determined, at the end of the experiment, using the
Lowry assay.
For endo-metabolites measurements from stable (13C)-tracing and diethyl-
succinate-rescue experiments as well as for blood mannose levels determination, an
Exactive Orbitrap mass spectrometer (Thermo Fisher Scientific) was used together
with a Thermo Fisher Scientific Accela HPLC system. The HPLC setup consisted of
a ZIC-pHILIC column (SeQuant, 150 mm × 2.1 mm, 5 µm, Merck KGaA) with a
ZIC-pHILIC guard column (SeQuant, 20 mm × 2.1 mm) and an initial mobile
phase of 20% 20 mM ammonium carbonate, pH 9.4 and 80% acetonitrile.
Metabolites extracts (5 µl) were injected and metabolites were separated over a
15-min mobile phase gradient, decreasing the acetonitrile content to 20%, at a flow
rate of 200 μl/min and a column temperature of 45 °C. All metabolites were
detected across a mass range of 75–1000m/z using the Exactive mass spectrometer
at a resolution of 25,000 (at 200m/z), with electrospray ionization and polarity
switching to enable both positive and negative ions to be determined in the same
run over a total analysis time of 23 min. For blood mannose levels determination,
longer runs of 37 min, a 30 min gradient with the same solvent was used, at a flow
rate of 100μl/min and a column temperature of 30 °C, as previously described21.
Lock masses were used and the mass accuracy obtained for all metabolites was
below 5 p.p.m. Data were acquired with Thermo LCquan 2.7 (Thermo Fisher
Scientific) software.
For determination of intracellular lactate and succinate levels in CD11b+ LP
mononuclear cells (described further below), shRNAs-transduced BMDMs as well
as for exo-metabolites measurement, a SCIEX TripleTOF5600+ mass spectrometer
equipped with on-line UPLC Agilent 1290 was used. MS acquisition was done in
negative polarity. Chromatographic separations occurred on a Sequant pZIC-
HILIC (150×2.1 mm, Merck Millipore) capillary column, packed with 5-µm
polymer with an HILIC SecurityGuard (ULTRA Cartridge UHPLC HILIC 2.1 mm,
Phenomenex). A gradient of eluents A (acetonitrile) and B ((NH4)2CO3 20 mM+
0.1% NH4OH) was used to achieve separation (200 µl/min flow rate), from 20% B
to 80% B in 15 min; the column temperature was set at 45 °C, while the
autosampler was set at 4 °C. Full scan spectra were acquired in the mass range from
m/z 75 to 1000. The mass accuracy obtained for all metabolites was below 5 p.p.m.
Acquired data were analyzed using MultiQuant Full 3.0.3 (SCIEX) software.
Measurement of MPI activity. Enzymatic activity of MPI was determined spec-
trophotometrically in cultured BMDMs and each cell line tested by a coupled
enzymatic reaction, as previously reported21. Briefly, cell pellets were lysed by three
freezing/thawing cycles. Eighty micrograms of post-nuclear protein fractions were
incubated in a buffer containing 200 mU of phosphoglucose isomerase, 500 mM
glucose-6-phosphate dehydrogenase, 1 mM NADP+, 40 mM Tris-HCl, pH 7.4,
6 mM MgCl2, 5 mM Na2HPO4/KH2PO4. Reactions were started by addition of
1 mM mannose-6-phosphate, and the production of NADPH was assessed at room
temperature by measuring the OD at 340 nm.
shRNA transductions. The lentiviral non-targeted NTC shRNA and shRNA
plasmids against Mpi, Hif1a, and Mrc1 were purchased from Sigma-Aldrich and
identified as follows: Mpi-1 shRNA, TRCN0000252480 (5′-CCGGAGATC
CTTGACAACCGTATTTCTCGAGAAATACGGTTGTCAAGGATCTTTTTTG-
3′); Mpi-2 shRNA, TRCN0000252478 (5′-CCGGAGTAAATTTGGCATTAGTA
ACCTCGAGGTTACTAATGCCAAATTTACTTTTTTG-3′); Hif1a-1 shRNA,
TRCN0000232220 (5′-CCGGCCCATTCCTCATCCGTCAAATCTCGAGATT
TGACGGATGAGGAATGGGTTTTTG-3′); Hif1a-2 shRNA, TRCN0000232222
(5′-AATTCAAAAATGGATAGCGATATGGTCAATGCTCGAGCATTGACCA
TATCGCTATCCA-3′); Mrc1-1 shRNA, TRCN0000054794 (5′-CCGGGCACCCA
TTTAATGTACCCATCTCGAGATGGGTACATTAAATGGGTGCTTTTT-3′);
Mrc1-2 shRNA, TRCN0000054795 (5′-CCGGCCTCTGGTGAACGGAATGA
TTCTCGAGAATCATTCCGTTCACCAGAGGTTTTT-3′). Lentiviral plasmids
were transfected into HEK293T cells together with packaging and envelope plas-
mids (psPAX2 and VSV-G) using the calcium phosphate procedure. Two days
after transfection, the growth medium containing lentiviruses was filtered through
a 0.45-μm pore filter, mixed with 4 µg/ml Polybrene (H9268, Sigma-Aldrich) and
transferred to the recipient BMDMs. HEK293T cells were further cultured in fresh
medium for 24 h. Next day, infection was repeated as above. After lentivirus
infection, BMDMs were selected with 1 μg/ml Puromycin (Sigma-Aldrich, Cat#:
P9620) for 48 h. Then, medium was changed and BMDMs treated as
described above.
Cloning and overexpression of mouse Mpi and Pmm2. The blasticidin S dea-
minase cassette was subcloned from the lentiCRISPR v2-Blast transfer vector
(purchased from Addgene) into the RsrII–NheI sites of a bidirectional miRNA
reporter lentiviral vector (kindly provided by Dr. Simone Cenci, IRCCS San Raf-
faele Scientific Institute) described previously40,41. The newly generated transfer
vector, named BSD1, was used for cloning either mouse Mpi or mouse Pmm2
cDNAs. For this aim, RNA was extracted from mouse liver by the RNeasy Plus
Mini Kit and retro-transcribed into complementary DNA by SuperScript™ II
Reverse Transcriptase (18064014, Thermo fisher Scientific). Mouse Mpi and Pmm2
cDNAs were amplified by Platinum™ PCR SuperMix High Fidelity (12532016,
Thermo fisher Scientific) according to the manufacturer’s instructions using the
following primers: Mpi (forward: 5′-GCGCCGACCGGTATGGCGAGTCCGC-
GAGT-3′; reverse: 5′-GGCGCCGTCGACCTACAGCAGACAGCAGGCCC-3′);
Pmm2 (forward: 5′-GCGCCGACCGGTATGGCCACTCTCTGTCTCTTCGAC-3′;
reverse: 5′-GGCGCCGTCGACTCAAGGGAAGAGCCCCTCACAG-3′). Ampli-
fied mouse Mpi and Pmm2 cDNAs were then cloned into the AgeI–SalI sites of
BSD1 vector. Lentiviral stocks were prepared, concentrated, and titered as pre-
viously described42. Briefly, self-inactivating (SIN) LV vector were produced using
either the empty or cDNA- cloned BSD1 transfer vector, the packaging plasmid
pMDLg/pRRE, Rev-expressing pCMV-Rev, and the VSV-G envelop-encoding
pMD2.VSV-G plasmids. BMDMs were transduced with a MOI= 5. Two days after
the transduction, BMDMs were selected with 1 μg/ml Blasticidin S (R21001, Gibco)
for 72 h. Then, medium was changed and BMDMs treated as described above .
Induction and macroscopic assessment of colitis in mice. For the evaluation of
protective (prophylactic) efficacy of mannose against colitis in mice, seven-week-
aged C57BL/6N mice were pre-treated with or without 20% (w/v) D-mannose given
in drinking water ad libitum for 2 weeks. Then, colitis was induced by adminis-
tration of 3% dextran sodium sulfate (DSS) (36–50 kDa, colitis grade MP Biome-
dicals) in filter-purified drinking water ad libitum for 7 days. Throughout DSS
administration, mice were treated with 200 µl of either water or 20% (w/v) man-
nose by oral gavage twice a day. The severity of colitis was assessed daily by
recording body weights (expressed as the percent of change of the weight at the
start of DSS treatment for each mouse). To assess macroscopic symptoms of
inflammation, feces were collected daily from each mouse and evaluated for con-
sistency and the presence of occult blood by Hemoccult SENSA (Beckman Coul-
ter). The disease activity index43 (DAI) was then calculated as the average of three
different parameters: body weight loss (score 1: 1–5%; score 2: 5–10%; score 3:
10–15%; score 4: more than 15%), blood in the stools (score 0: no blood; score 2:
occult blood; score 4: visible anal bleeding), and stools consistency (score 0: well
formed; score 2: soft; score 4: diarrhea). At the end of treatment (day 7 of DSS
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treatment), mice were killed, colons were excised, and their lengths, from the end of
the cecum to the anus, were measured.
For the evaluation of therapeutic efficacy of mannose against DSS-induced
colitis, 7-week-aged C57BL/6 mice were provided with 3% (w/v) DSS in drinking
water ad libitum for 5 days and then returned to normal drinking water until the
end of the experiment (day 10). Starting from day 3 of DSS administration—time
sufficient to induce formation of either soft stools or the appearance of occult blood
in feces—mice were treated with 200 µl of either water or 20% (w/v) mannose by
oral gavage twice a day, until the end of the experiment. Macroscopic symptoms of
inflammation and colon length were measured as described above.
Histological assessment of colitis in mice and immunohistochemistry. Colons
were collected from sacrificed mice at the end of each treatment schedule, as
described above, fixed in 10% neutral-buffered formalin, and embedded in paraffin.
Serial 5 µm microtome-cut sections were then stained with hematoxylin and eosin
(Sigma-Aldrich). Slides were acquired with an Aperio AT2 digital scanner (Leica
Biosystems) and analyzed with an Aperio Imagescope (Leica Biosystem). Scoring of
colonic inflammation was determined as reported by Nagahama et al.44 with minor
modifications, by assessing mucosa thickening, inflammatory cells, and submucosa
cell infiltration. Each criterion was scored as 0–4, and the sum of each score was
defined as the histological score.
Immunohistochemical staining of HIF-1α was performed on colon sections of
mice with the anti-HIF-1 alpha antibody (Abcam ab2185, 1:2000) and antigen
unmasking in citrate buffer. Sections were incubated with specific Detection KIT-
HRP (Abcam, ab236469) according to the manufacturer’s instructions, then
counter-stained with hematoxylin to visualize nuclei, dehydrated and mounted in
DPX (Sigma-Aldrich). Bright-field images were acquired with an Aperio AT2
digital scanner (Leica Biosystems) and analyzed with an Imagescope (Leica
Biosystem) or using a Zeiss Axio Imager M2m microscope with a ×10 or ×20
objective.
FACS characterization of colon lamina propria-infiltrating immune cells. Colon
lamina propria mononuclear cells (LPMCs) were obtained from healthy and
inflamed colonic tissues, as previously described44. Briefly, at the end of DSS
treatment, colons were cut longitudinally and washed in PBS containing 5% FBS
and 2mM EDTA for 10 min at 37 °C. Enzymatic digestion was then performed in
RPMI 1640 medium supplemented with 10% fetal bovine serum, 0,25 mg/ml
collagenase type VIII (Sigma-Aldrich), 20 µg/ml DNase I (Roche Diagnostics), 100
U/ml penicillin, and 100 mg/ml streptomycin for 45 min at 37 °C with gentle
shaking. Then, cell suspension was washed with FACS buffer (PBS supplemented
with 0.5% BSA and 1mM EDTA) and centrifuged at 300g for 8 min, before being
clarified over a 70-µm cell strainer.
To characterize the different myeloid populations, 1 × 106 murine LPMCs were
stained for 20 min at 4 °C with the following fluorochrome-conjugated antibodies
(Biolegend) diluted 1:250 in FACS buffer: FITC-conjugated anti-mouse CD45
(clone 30-F11), APC-conjugated anti-mouse CD11c (clone N418), Pe-Cy7-
conjugated anti-mouse/human CD11b clone (M1/70), Ly6C PerCPCy5.5-
conjugated anti-mouse Ly6C (clone HK1.4), PE-conjugated anti-mouse F4/80
(clone BM8), APC-Cy7-conjugated anti-mouse Ly6g (clone 1A8), and brilliant
violet 510-conjugated anti-mouse MHCII (clone M5/114.15.2). Cell populations
were gated on DAPI-negative (live) single cells and identified as follows: monocytes
(CD45+, CD11b+, CD11c−, F4/80−, Ly6C+), macrophages (CD45+, CD11b+,
CD11c−, F4/80+, Ly6C−) and neutrophils (CD45+, CD11b+, CD11c−, F4/80−,
Ly6G+, Ly6C+).
To assess infiltration of regulatory T cells (Tregs, identified as CD45+, CD3+,
CD4+, CD25+, Foxp3+ cells) 1 × 106 murine LPMCs were washed in PBS and
stained with Zombie Violet (Biolegend) for 20 min at 4 °C. Afterwards samples
were stained with the following fl for 20 mi-conjugated antibodies (Biologend)
diluted 1:250 in FACS buffer: FITC-conjugated anti-mouse CD45 (clone 30-F11),
APC-conjugated anti-mouse CD25 (clone PC61), PerCPCy5.5-conjugated anti-
mouse CD4 (GK1.5), and APC-Cy7-conjugated anti-mouse CD3e (clone 145-
2C11). Cells were then fixed and permeabilized with BD Cytofix/Cytoperm
Fixation/Permeabilization Solution Kit for 10 min at RT, according to the
manufacturer’s protocol. Cells were then stained with Pe-Cy7-conjugated anti-
mouse Foxp3 antibody (clone FJK-16s, eBioscience) diluted 1:250. To assess MRC1
levels in BMDMs transduced with lentiviral non-targeted shRNA and shRNA
plasmids against Mrc1, cells were incubated with Aqua live/dead viability staining
marker (Invitrogen, Carlsbad, US) and an Fc block reagent (purified anti-CD16/32,
clone 93, eBioscience-Thermo Fisher, Waltham, US). Then, the following murine
antibodies, diluted in PBS−/− containing 2% FCS, 2 mM EDTA, and 0.05% NaN3,
were used: anti-CD45-FITC (clone 30-F11), anti CD11b-Pacific Blue (clone M1/
70), anti-CD11c-APC (clone N418), anti-F4/80-PE (clone BM8), and anti-CD206-
PeCy7 (clone C068C2) from Biolegend (San Diego, US). All samples were acquired
using BD FACSCanto II (BD Bioscience); data were analyzed with FlowJo software
(Treestar).
Immunomagnetic sorting and analysis of CD11b+ LPMCs. CD11b+ were iso-
lated from LPMCs, obtained from healthy and inflamed colonic tissues, by mag-
netic cell sorting using CD11b microbeads (Miltenyi Biotec) according to the
manufacturer’s instructions. RNA was extracted by the RNeasy Plus Mini Kit
(74136, Qiagen) and used for real-time qPCR analyses as described above. The
relative quantification of Il1b mRNA levels was carried out with the comparative
threshold cycle method using β-actin (Actb) for normalization. For determination
of lactate and succinate levels, 1 × 106 live (trypan blue-negative) CD11b+ cells
were incubated with 300 μl of ice-cold extraction solution and extracted metabo-
lites measured by LC-MS as described above.
Endotoxin-induced model of sepsis. Seven- to 9-week-aged male Balb/c mice
were stimulated with a single intraperitoneal (i.p) injection of 20 mg/kg O55:B5
LPS diluted in saline solution and treated with 2 g/kg mannose, solubilized in saline
solution, given hourly by i.p. injections for up to six times. LPS-untreated mice
(when used) and mannose-untreated mice received corresponding volumes of
saline solution, as control. Progression of disease was determined by two blinded
investigators by monitoring mice every 2 h after LPS injection for clinical signs of
endotoxic shock based on coat and eyes appearance, level of consciousness, loco-
motor activity, respiration rate, and quality scored between 0 and 4, as previously
reported44. The humane end-point for the experiment was achieved when a
combined score >12 or a maximal score in one individual parameter was
totalized.
For IL-1βmeasurement and peritoneal macrophages isolation, control mice and
counterparts stimulated with 20 mg/kg O55:B5 LPS were treated with either 2 g/kg
mannose or saline control (vehicle) solution given hourly by i.p. injection. After 3 h
LPS injection, mice were sacrificed in a CO2 chamber. Then, peritoneal
macrophages were isolated as previously reported45, from which HIF-1α levels
were determined by western blotting, as well as blood samples collected, for ELISA
—determination of serum IL-1β levels, as described above.
Ethical approval of animal studies. Male and female C57BL/6N and Balb/c mice
were obtained from Charles River and bred in house. Animals were housed in
individual ventilated cages in a barrier facility proactive in environmental
enrichment under specific pathogen-free conditions in line with European Union
regulations. All experimental animal procedures were approved by the Institutional
Animal Committee of San Raffaele Scientific Institute.
Statistics and reproducibility. Two-tailed Student t-tests were carried out with
GraphPad Prism 7 software. When unequal variances between experimental groups
were computed, Welch’s correction was applied. Potential outliers in Fig. 1c were
identified by the ROUT method according to GraphPad guidelines and removed
from experimental groups for more accurate calculation of statistical difference
between means. For in vitro studies, statistical analyses were carried out using the
number of wells as the sample size (n). Wells represent technical replicate samples
setup and assessed under identical conditions in a single experiment. Details of the
numbers of wells assessed and the number of independently replicated experiments
are provided in each figure legend.
Reporting Summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All other data are available from the corresponding author upon reasonable
requests. Source data are provided with this paper.
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